The investigators assembled a retrospective case-control dataset from four prospectively collected Japanese cohorts. The cohort comprised 34 adults diagnosed with sepsis and 46 adults with clinically similar conditions classified as sepsis mimics. Serum samples were analyzed using a 92-protein inflammation-focused panel from Olink. The authors reported that this work was a secondary analysis; the Ethics Review Committee of Nagoya University Graduate School of Medicine approved the study (approval number 2023-0314). The source noted that participant-level data are not publicly available because of consent and governance restrictions, but aggregate protein-level results appear in the supplementary materials.
Data indicated no single protein met the false discovery rate threshold after multiple-testing correction; the lowest FDR-adjusted P value reported was 0.345. The study team trained three predictive algorithms and assessed performance with repeated nested cross-validation. The predefined primary model—an elastic-net classifier—produced an area under the receiver operating characteristic curve of 0.442 when cross-validation predictions were averaged per participant (95% confidence interval, 0.315–0.574). That AUC lies near chance-level classification.
Random forest and gradient boosting algorithms were also trained and evaluated. According to the report, these alternative models likewise showed no clear evidence of discrimination above chance. The authors performed sensitivity analyses restricted to all-serum samples and to samples that passed quality-control filters; confidence intervals from those sensitivity analyses included chance performance as well. The source did not provide additional methodological details such as exact model hyperparameters, feature-selection thresholds, or the number of cross-validation repeats beyond noting the use of repeated nested cross-validation.
Across the 92 measured analytes, the investigators observed between-group differences that did not survive FDR correction. The paper explicitly reports that no protein reached the adjusted significance threshold, and the smallest adjusted P value was 0.345. In practice, this meant that a single snapshot of an inflammation-oriented proteomic panel did not provide robust, reproducible separation of patients with sepsis from those with sepsis-like presentations in this dataset.
The authors emphasized that machine-learning classifiers applied to these single-timepoint measurements failed to yield clinically useful discrimination. The source did not claim any specific analyte or combination to be diagnostic. Where model outputs were reported, confidence intervals encompassed chance-level performance, signaling low discriminatory signal in these data as measured and analyzed.
The manuscript reports that each parent cohort had institutional ethics approval and that written informed consent was obtained from participants or their legal guardians according to the original protocols; an opt-out mechanism was additionally used for this secondary analysis. The authors stated that participant-level data are not publicly available because of the consent and institutional approvals governing the parent studies, and that requests for deidentified data require institutional review and approvals.
Several authors disclosed relationships with industry. The source lists collaborative research, consulting, lecture fees, speaker fees, and research grants involving multiple companies and foundations; those activities were described as outside the submitted work. The article is a preprint and has not been peer reviewed; the source cautions that it should not be used to guide clinical practice.
The authors identified key limitations directly in the report. First, this analysis used a single timepoint measurement of inflammation-focused proteins; the source noted that integration with clinical information and longitudinal measurements warrants further investigation. Second, the study was a retrospective secondary analysis of samples collected within parent cohorts; the report did not provide details on matching criteria or the full spectrum of clinical diagnoses included among the sepsis mimics. Third, participant-level data remain restricted and require institutional approval for access, which limits immediate external validation.
Unanswered clinical questions—explicitly mentioned by the authors—include whether combining proteomic signals with bedside clinical variables or serial sampling over time would improve discrimination between sepsis and mimics. The source did not report any regulatory milestones, planned prospective validation trials, or specific timelines for follow-up work. Given the reported null discrimination from a single Olink panel measurement, further studies will need to test whether different assay targets, temporal sampling strategies, or integrated clinical-biomarker models can produce clinically actionable performance.